CHIARINI, Francesca
 Distribuzione geografica
Continente #
NA - Nord America 725
EU - Europa 641
AS - Asia 249
SA - Sud America 2
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 1.619
Nazione #
US - Stati Uniti d'America 723
HK - Hong Kong 203
IT - Italia 175
GB - Regno Unito 172
SE - Svezia 160
FI - Finlandia 36
CN - Cina 32
IE - Irlanda 32
DE - Germania 31
FR - Francia 7
SG - Singapore 7
NL - Olanda 6
BG - Bulgaria 4
UA - Ucraina 4
CZ - Repubblica Ceca 3
ES - Italia 3
TR - Turchia 3
BE - Belgio 2
BR - Brasile 2
CA - Canada 2
RO - Romania 2
RU - Federazione Russa 2
VN - Vietnam 2
A2 - ???statistics.table.value.countryCode.A2??? 1
IN - India 1
JP - Giappone 1
MD - Moldavia 1
NZ - Nuova Zelanda 1
PL - Polonia 1
Totale 1.619
Città #
Ashburn 266
Hong Kong 202
Nyköping 145
Chandler 58
Fairfield 56
London 52
Houston 37
Dublin 32
Helsinki 32
Woodbridge 32
Southend 30
Parma 26
Cambridge 19
Seattle 17
Wilmington 16
Bologna 14
Shanghai 13
Modena 12
Reggio Emilia 12
Washington 12
Chiswick 11
Kilburn 11
Hounslow 9
Ann Arbor 8
Milan 8
New York 8
San Diego 8
Islington 7
Padova 7
Torre del Greco 7
Ferrara 6
Glasgow 6
Munich 6
Prescot 6
Amsterdam 5
Carpi 5
Dearborn 5
Naples 5
Rome 5
Arceto 4
Beijing 4
Jacksonville 4
Princeton 4
Sofia 4
Boardman 3
Brno 3
Eugene 3
Lappeenranta 3
Perugia 3
Southwark 3
Venice 3
Aberdare 2
Brentford 2
Brussels 2
Chicago 2
Curtatone 2
Dong Ket 2
Falls Church 2
Frattamaggiore 2
Giuliano di Roma 2
Gualtieri 2
Izmir 2
La Spezia 2
Madrid 2
Montecatini Terme 2
Osasco 2
Paris 2
Pescara 2
Portici 2
Ravenna 2
Roncoferraro 2
Stockholm 2
Urbino 2
Wandsworth 2
Acton 1
Andover 1
Auckland 1
Bilbao 1
Bonn 1
Bonndorf 1
Bremen 1
Brunico 1
Bucharest 1
Catania 1
Central 1
Chisinau 1
Chiyoda-ku 1
Chongqing 1
Edinburgh 1
Fremont 1
Galati 1
Grafing 1
Greenwich 1
Junction City 1
Kemerovo 1
Lawrence 1
Lodi 1
Luni 1
Lurago D'erba 1
Medolla 1
Totale 1.329
Nome #
Dual inhibition of PI3K/mTOR signaling in chemoresistant AMLprimary cells. 197
Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: Turning offthe prosurvival ER chaperone BIP/Grp78 and turning on the proapoptotic NF-κB 132
Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer 124
Antigene MYCN Silencing by BGA002 Inhibits SCLC Progression Blocking mTOR Pathway and Overcomes Multidrug Resistance 66
The Combination of AHCC and ETAS Decreases Migration of Colorectal Cancer Cells, and Reduces the Expression of LGR5 and Notch1 Genes in Cancer Stem Cells: A Novel Potential Approach for Integrative Medicine 52
Targeting metabolic vulnerabilities and aberrant signal transduction pathways in paediatric T-cell Acute Lymphoblastic Leukaemia (T-ALL) 36
Lamin A and the LINC complex act as potential tumor suppressors in Ewing Sarcoma 35
A role of PI-PLCb1 in G1/S transition in human erythroleukemia k562 cells 25
Molecular Signature of Biological Aggressiveness in Clear Cell Sarcoma of the Kidney (CCSK) 23
Understanding the Roles of the Hedgehog Signaling Pathway during T-Cell Lymphopoiesis and in T-Cell Acute Lymphoblastic Leukemia (T-ALL) 22
Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting 20
Autophagy in acute leukemias: a double-edged sword with important therapeutic implications 20
Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235, against T-cell acute lymphoblastic leukemia 19
Involvement of nuclear PLC{beta}1 in lamin B1 phosphorylation and G2/M cell cycle progression 19
Assessment of the structural and functional characteristics of human mesenchymal stem cells associated with a prolonged exposure of morphine 18
B-ALL Complexity: Is Targeted Therapy Still A Valuable Approach for Pediatric Patients? 18
Toxicity of antimony trioxide nanoparticles on human hematopoietic progenitor cells and comparison to cell lines 17
Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS 17
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients 17
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-ami ne (A443654) in T-cell acute lymphoblastic leukemia 17
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia 17
Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107) 17
Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels 16
Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia 16
AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications 16
Cellular senescence in vascular wall mesenchymal stromal cells, a possible contribution to the development of aortic aneurysm 15
Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 15
13. PLCβ1a and PLCβ1b selective regulation and cyclin D3 modulation reduced by kinamycin F during k562 cell differentiation 15
Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy 15
Implication of Cellular Senescence in Osteoarthritis: A Study on Equine Synovial Fluid Mesenchymal Stromal Cells 15
Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of MLL-Rearrangements: A Novel Therapeutic Strategy for Pediatric AML 14
Assessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics 14
Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment 14
PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors 14
Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia 13
Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling 13
Synergistic induction of PI-PLCbeta1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes 13
Activity of the selective IκB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a 13
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response 13
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells 12
Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells 12
Therapeutic targeting of CK2 in acute and chronic leukemias 12
Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor perifosine in acute myeloid leukemia cells 12
The emerging role of the phosphatidylinositol 3-kinase/Akt/mTOR signaling network in normal myelopoieis and leukemogenesis 12
K562 cell proliferation is modulated by PLCβ1 through a PKCα-mediated pathway 11
The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation 11
Targeting Signaling Pathways in T-cell acute lymphoblastic leukemia initiating cells 11
Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies 11
Pediatric early T-cell precursor leukemia with NF1 deletion and high-sensitivity in vitro to tipifarnib 11
Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia 11
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance 10
Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update 10
Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia 10
Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside 10
Pathobiology and Therapeutic Relevance of GSK-3 in Chronic Hematological Malignancies 10
The cyclin-dependent kinase inhibitor roscovitine and the nucleoside analog sangivamycin induce apoptosis in caspase-3 deficient breast cancer cells independent of caspase mediated P-glycoprotein cleavage 10
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia 10
Targeting the phosphatidylinositol 3-kinase/Akt/mTOR signaling network in acute myelogenous leukaemia 9
Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway 9
Age-Related Alterations Affecting the Chondrogenic Differentiation of Synovial Fluid Mesenchymal Stromal Cells in an Equine Model 9
MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia 9
PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy 9
Phospholipase C-β1 interacts with cyclin E in adipose- derived stem cells osteogenic differentiation 9
Lamin A and Prelamin A Counteract Migration of Osteosarcoma Cells 8
Dual inhibition of class IA phoshatidylinositol 3-kinase and mTOR as a new therapeutic option for T-cell acute lymphoblastic leukemia 8
Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies 8
Targeting Wnt/β-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia 8
GSK-3: a multifaceted player in acute leukemias 8
Current treatment strategies for inhibiting mTOR in cancer 8
Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment 8
Enhancing the effectiveness of nucleoside analogs with mTORC1 blockers to treat acute myeloid leukemia patients 8
Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 8
Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (Review) 8
Dual Inhibition of Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin: a Therapeutic Strategy for Acute Leukemias 8
Temsirolimus, An Allosteric mTORC1 Inhibitor, Is Synergistic with Clofarabine in AML and AML Leukemia Initiating Cells 7
The Unfolded Protein Response: A Novel Therapeutic Target in Acute Leukemias 7
New advances in targeting aberrant signaling pathways in T-cell acute lymphoblastic leukemia 7
Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia 7
The Emerging Role of the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cell Biology 7
Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene 7
The Role Played by Wnt/β-Catenin Signaling Pathway in Acute Lymphoblastic Leukemia 6
Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms 6
Advances in Targeting Signal Transduction Pathways 6
The Cutting Edge: The Role of mTOR Signaling in Laminopathies 6
The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis 6
Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells 6
Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia 6
The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resisten human T-acute leukemia cells by a JNK-dependent mechanism 4
Totale 1.639
Categoria #
all - tutte 30.829
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.829

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201924 0 0 0 0 0 0 0 0 2 5 9 8
2019/202091 8 1 1 4 10 14 14 10 8 7 7 7
2020/2021132 8 5 10 14 5 19 12 15 10 7 14 13
2021/202290 3 6 4 13 2 4 8 7 8 7 18 10
2022/2023569 7 11 12 27 42 70 30 62 110 27 60 111
2023/2024701 36 30 47 153 133 66 177 59 0 0 0 0
Totale 1.639